| Literature DB >> 30815015 |
Sheida Nasr Isfahani1, Ziba Farajzadegan2, Ali Mohammad Sabzghabaee3, Alireza Rahimi4, Shiva Samasamshariat5, Nastaran Eizadi-Mood3.
Abstract
BACKGROUND: Paraquat (PQ) poisoning is a serious public health problem in many countries. In spite of different treatments, the mortality is still high. We performed a meta-analysis to see whether hemoperfusion (HP) in combination with other treatments reduces the mortality more than HP alone in patients with PQ poisoning.Entities:
Keywords: Hemoperfusion; meta-analysis; mortality; paraquat; poisoning
Year: 2019 PMID: 30815015 PMCID: PMC6383336 DOI: 10.4103/jrms.JRMS_478_18
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Figure 1A flowchart of literature searches in this meta-analysis
Information of articles compared patients with paraquat poisoning received hemoperfusion plus conventional therapy (Group 1: Hemoperfusion) versus those received only conventional therapy (Group 2: Nonhemoperfusion)
| First author/year | Study design/area | Sample size (Group 1/Group 2) | Group 1 | Group 2 | Time to HP (h) | Duration/times of HP | Mortality(%) | F |
|---|---|---|---|---|---|---|---|---|
| Rao | Retrospective/India | 101 (63/38) | HP + Con. (AC, GL) | Con. (AC, NAC, antioxidants) | 33 patients | NM/NM | Group 1=42.9 (HP <6 h=6.1 and in HP >6 h=86.20) | 60 days |
| Group 2=92.10 | ||||||||
| Li | Retrospective/China | 183 (65/75) | HP + Con. (sodium bicarbonate AC, GL, cathartic, diuresis) | Con. (sodium bicarbonate, AC, GL, cathartic, diuresis) | 1-2 h after admission | 3-4 h/4 times | Group 1=56.90 | 60 days |
| Group 2=78.7 | ||||||||
| Jagadeesan | Retrospective/India | 10 (5/5) | HP + Con. (AC, GL, HD) | Con. (AC, GL, HD) | NM | NM/NM | Group 1=100 | I h |
| Group 2=100 | ||||||||
| Sun | Retrospective/Korea | 788 (594/194) | HP + Con. (GL, fuller earth, antioxidant, mannitol) | Con. (GL, fuller’s earth, antioxidant, mannitol) | NM | NM/NM | Group 1=76.26 | 3 months |
| Group 2=95.87 | ||||||||
| Lee | Retrospective/Korea | 272 (110/162) | HP + Con. (GL, fuller’s earth, mannitol) | Con. (GL, fuller’s earth, mannitol) | NM | NM/NM | Group 1=71.81 | 3 months |
| Group 2=88.27 |
NM=Not mentioned; PQ=Paraquat; HP=Hemoperfusion; AC=Activated charcoal; GL=Gastric lavage; Con=Conventional therapy; NAC=N-acetyl cysteine; HD=Hemodialysis; IH=In hospital; F=Follow-up
Information of articles compared patients with paraquat poisoning received hemodialysis plus conventional therapy (Group 1: Hemodialysis) versus those received only conventional therapy (Group 2: Nonhemodialysis)
| First author/year | Sample size (Group 1/Group 2) | Age (years) | Urine paraquat test | PQ Concentration (μg/ml) | Time from ingestion to arrival (h) |
|---|---|---|---|---|---|
| Rao | 101/ (63/38) | 26.97±7.679 | Positive | NM | NM |
| Li | 183/(Group 1.1=65/Group 1.2=43/Group 2=75) | Median age | 5-200 μg/ml | Group 1=22.95±10.41 | Group 1: 7.5 (0.5-20.5)/Group 2:12.2 (0.5-22.0) median ( range) |
| Group 1=37 | |||||
| Group 2=21.56±11.7 | |||||
| Group 2=36 | |||||
| Jagadeesan | 10/(5/5) | Median age, 28.5 | NM | NM | 2 patients<2 h, |
| Sun | 788/ (594/194) | S=47±14 | Negative in 26 cases of survival and four cases of nonsurvival group | S=0.4±0.7 | S=8.7±17.2 |
| NS=59±16 | NS=80.3±123.1 μg/ml | NS=6.1±14.4 | |||
| Lee | 272 (110/162) | Median age | Positive | NM | NM |
| S=49 | |||||
| NS=63 |
NM=Not mentioned in the article; S=Survived, NS=Nonsurvived, PQ=Paraquat
Figure 2Funnel plot of hemoperfusion and conventional therapy versus conventional therapy in paraquat poisoning mortality
Figure 3Forest plot for comparison effect of hemoperfusion and conventional therapy (Favor A) versus conventional therapy (nonhemoperfusion) (Favor B) on mortality in paraquat poisoning
Information of articles compared patients received conventional therapy plus hemoperfusion (Group 1) versus those received conventional therapy + hemoperfusion + other treatments (Group 2)
| First author/year | Study design/area | Sample size (Group 1/Group 2) | Group 1 | Group 2 | Time to HP (h) | HP duration/times | Mortality (%) Group 1/Group 2 | F |
|---|---|---|---|---|---|---|---|---|
| Tsai | Case-control/Taiwan | 32 (16/16) | HP + Con. (AC) | HP + MP + Con. (AC) | NM | NM | 87.5/87.5 | 7 days |
| Koo | RCT (prospective)/Korea | 80 (44/36) | HP + Con. (AC or Fuller’s earth, GL, DX, Vit C) | HP + CVVH + Con. (AC or fuller’s earth. HP, DX, Vit C) | Group 1: 6.4±3.4 | 6 h/1 or 2 times (Group 1 | 63.6/66.7 | 3 months |
| Group 2: 5.7±2.9 | ||||||||
| Gao | Retrospective (RCT)/China | 684 (458/226) | HP + Con. (GL, antioxidant, DX, Vit C) | HP + CVVH + Con. (GL, antioxidants, DX, Vit C) | Group 1: 4.8±2.1 | 6 h/1 or 2 times | 57.4/58.4 | IH |
| Group 1 | ||||||||
| Group 2: 5.2±3.7 | Group 2 | |||||||
| Shi | Retrospective/china | 119 (37/82) | HP + Con. (GL, catharsis, diuresis, hormones, glutathione, and HD for ARF) | HP + XBJ, Ulinastatin + Con. ( GL, catharsis, diuresis, hormones, glutathione, HD for ARF) | NM | 2-3 h/once daily | 70.27/46.34 | 28 days |
| Wu | Retrospective/Taiwan | 1811 (1046/765) | HP + Con. | HP + MP/CP + Con. (DX) | NM | NM/2.0±1.4 S | 75.7/70.7 | NM |
| Ghorbani | RCT double blind/IRAN | 47 (23/24) | HP + Con. (AC, GL, and HD for renal replacement if necessary | AC, GL, HP, and HD for renal replacement if necessary, CP, MP | NM | 8 h/2 times | 60.9/25 | IH |
| Li | Retrospective/China | 108 (65/43) | HP + Con. | HP + CVVH + Con. | NM | First day: 3-4 h/2 times next 2 day 6-8 h daily | 56.90/53.50 | 60 day |
NM=Not mentioned; PQ=Paraquat; HP=Hemoperfusion; Con=Conventional; AC=Activated charcoal; GL=Gastric lavage; CVVH=Continues venovenous hemofiltration; HD=Hemodialysis; S=Survived patients; NS=Nonsurvived patients; DX=Dexamethasone; MP=Methyl prednisolone; CP=Cyclophosphamide; CRRT=Continues renal replacement therapy; IH=In hospital; F=Follow-up; Vit=Vitamin
Information of articles compared patients received conventional therapy plus hemoperfusion (Group 1) versus those received conventional therapy + hemoperfusion + other treatments (Group 2)
| First author/year | Study design/area | Sample size (Group 1/Group 2) | Age (years) | Urine paraquat test | PQ concentration μg/ml) | Time from ingestion to arrival (hours) | CASPscore |
|---|---|---|---|---|---|---|---|
| Tsai | Case-control/Taiwan | 32 (16/16) | Group 1=44.2±15.6 | Positive | Group 2: 47.8±97.3 | Group 2: 6.4±4.4 | 82 |
| Group 2=43.5±4.2 | Group 1: 17.5±20.5 | Group 1: 6.7±4.8 | |||||
| S=30.25±6.24 | S=0.25±0.19 | S=3±1.41 | |||||
| NS=45.79±14.56 | NS=37.29±74.77 | NS=7.04±4.57 | |||||
| Koo | RCT (prospective)/Korea | 80 (44/36) | Group 1=47±16 | 2.3% in Group 1 and 2.8% in Group 2 was negative | NM | NM | 83 |
| Group 2=43±17 | |||||||
| Gao | Retrospective/ (RCT) China | 684 (458/226) | Group 1=39±15 Group 2=37±19 | Group 1=0.1% | NM | NM | 87 |
| Group 2=0.2% was Negative | |||||||
| Shi | Retrospective/china | 119 (Group 1=37/Group 2.1=43 Group 2.2=39) | Group 1=35.25±8.75 Group 2=33.29±7.66 | NM | Group 1=12.26±4.59 | Group 1: 12.31±8.21 | 87 |
| Group 2=11.87±6.63 | Group 2: 10.32±6.47 | ||||||
| Wu | Retrospective/Taiwan | 1811 (1046/765) | S=38.6±14.9 | NM | NM | NM | |
| NS=50.4±17.5 | |||||||
| Ghorbani | RCT double-blind, IRAN | 47 (23/24) | Group 1=23.7±5 | Navy or dark | NM | Group 1=11 | 81 |
| Group 2=22.5±5 | Group 2=15 | ||||||
| Li | Retrospective/China | 183 (65/43) | NM | Urine paraquat concentration 5-200 μg/ml | Group 1: 22.95±10.41 | Group 1: 7.5 (0.5-20.5) | 88 |
| Group 2: 7.8 (0.5-19.0) (median and range) | |||||||
| Group 2: 20.82±9.26 |
S=Survivals; NS=Nonsurvivals; NM=Not mentioned in the article
Figure 4Forest plot of comparison effect of hemoperfusion (Favor A) versus hemoperfusion with other treatments (Favor B) on mortality in paraquat poisoning